| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry - paraffin section; human
| Guo Z, Lloyd R. Use of monoclonal antibodies to detect specific mutations in formalin-fixed, paraffin-embedded tissue sections. Hum Pathol. 2016;53:168-77 pubmed publisher |
- flow cytometry; human; 1:2000; loading ...; fig s2d
| Ebbing E, Medema J, Damhofer H, Meijer S, Krishnadath K, van Berge Henegouwen M, et al. ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. Oncotarget. 2016;7:10243-54 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...; fig 2b
| Castillo Martin M, Collazo Lorduy A, Gladoun N, Hyun G, Cordon Cardo C. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases. J Pediatr Urol. 2016;12:91.e1-7 pubmed publisher |
- western blot; human; fig 1a
| Zhang X, Jung I, Hwang Y. EGF enhances low-invasive cancer cell invasion by promoting IMP-3 expression. Tumour Biol. 2016;37:2555-63 pubmed publisher |
- immunohistochemistry - paraffin section; human; tbl 2
| Savci Heijink C, Halfwerk H, Hooijer G, Horlings H, Wesseling J, van de Vijver M. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015;150:547-57 pubmed publisher |
- immunohistochemistry; human; 1:200
| Kim G, Lee J, Choi Y, Lee K, Lee J, Nam J, et al. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer. BMC Cancer. 2014;14:959 pubmed publisher |
- immunohistochemistry; human; 1:500; fig 2
| Egloff A, Lee J, Langer C, Quon H, Vaezi A, Grandis J, et al. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Clin Cancer Res. 2014;20:5041-51 pubmed publisher |
| Mudduwa L, Peiris H, Gunasekara S, Abeysiriwardhana D, Liyanage N, Rayala S, et al. KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy. BMC Cancer. 2018;18:589 pubmed publisher |
| Lindberg O, McKinney A, Engler J, Koshkakaryan G, Gong H, Robinson A, et al. GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. Oncotarget. 2016;7:79101-79116 pubmed publisher |
| Robinson L, Jaing C, Pierce Campbell C, Magliocco A, Xiong Y, Magliocco G, et al. Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung. Br J Cancer. 2016;115:497-504 pubmed publisher |
| Wernicke A, Dicker A, Whiton M, Ivanidze J, Hyslop T, Hammond E, et al. Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiat Oncol. 2010;5:46 pubmed publisher |
| Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008;99:923-9 pubmed publisher |
| Pallis A, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, et al. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer. 2007;97:1560-6 pubmed |
